Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JW7D
|
|||
| Former ID |
DIB000741
|
|||
| Drug Name |
Omiganan
|
|||
| Synonyms |
CLS-001; MBI-594AN; MX-594AN; Omiganan (topical, acne/rosacea); Omiganan (topical, acne/rosacea), Biowest Therapeutics/Cutanea; Omiganan (topical, acne/rosacea), MIGENIX/Cutanea
Click to Show/Hide
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 3 | [1] | |
| Rosacea [ICD-11: ED90.0; ICD-10: L71.8, L71.9] | Phase 3 | [2] | ||
| Acne vulgaris [ICD-11: ED80; ICD-10: L70.0; ICD-9: 706.1] | Phase 2 | [2] | ||
| Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Phase 2 | [2] | ||
| External genital and perianal wart [ICD-11: 1A95; ICD-10: A63.0] | Phase 2 | [2] | ||
| Vulvar intraepithelial neoplasia [ICD-11: 2E67.10; ICD-10: N90.1, N90.2] | Phase 2 | [2] | ||
| Company |
Biowest Therapeutics Inc; Migenix
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C90H127N27O12
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC3C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N8CCCC8C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)N)N
|
|||
| InChI |
1S/C90H127N27O12/c1-5-51(4)75(92)85(127)113-68(41-50(2)3)80(122)109-67(32-18-38-102-90(98)99)79(121)114-71(44-54-48-105-62-27-12-8-23-58(54)62)86(128)116-39-19-34-74(116)84(126)112-70(43-53-47-104-61-26-11-7-22-57(53)61)82(124)115-72(45-55-49-106-63-28-13-9-24-59(55)63)87(129)117-40-20-33-73(117)83(125)111-69(42-52-46-103-60-25-10-6-21-56(52)60)81(123)110-66(31-17-37-101-89(96)97)78(120)108-65(30-16-36-100-88(94)95)77(119)107-64(76(93)118)29-14-15-35-91/h6-13,21-28,46-51,64-75,103-106H,5,14-20,29-45,91-92H2,1-4H3,(H2,93,118)(H,107,119)(H,108,120)(H,109,122)(H,110,123)(H,111,125)(H,112,126)(H,113,127)(H,114,121)(H,115,124)(H4,94,95,100)(H4,96,97,101)(H4,98,99,102)/t51-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-/m0/s1
|
|||
| InChIKey |
MVPAMLBUDIFYGK-BHDRXCTLSA-N
|
|||
| CAS Number |
CAS 204248-78-2
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00231153) Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.